

# Antonio Craxi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4540919/antonio-craxi-publications-by-citations.pdf>

**Version:** 2024-04-16

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

361  
papers

24,968  
citations

69  
h-index

151  
g-index

388  
ext. papers

28,463  
ext. citations

6.3  
avg, IF

6.39  
L-index

#	Paper	IF	Citations
361	Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 975-82	59.2	5551
360	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 161-176	18.8	1196
359	Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 1493-9	59.2	1103
358	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 821-9	13.4	589
357	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 896-904	13.4	550
356	Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 425-33	13.4	425
355	Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. <i>Gut</i> , <b>2004</b> , 53, 925-30	19.2	401
354	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2014</b> , 384, 403-13	40	394
353	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , <b>2018</b> , 67, 1754-1767	11.2	376
352	Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. <i>Gastroenterology</i> , <b>2004</b> , 126, 102-10	13.3	327
351	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , <b>2010</b> , 51, 1158-67	11.2	318
350	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , <b>2015</b> , 61, 506-14	11.2	311
349	A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. <i>Hepatology</i> , <b>2010</b> , 51, 1274-83	11.2	292
348	Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. <i>Journal of Hepatology</i> , <b>1991</b> , 13, 192-9	13.4	264
347	Extrahepatic morbidity and mortality of chronic hepatitis C. <i>Gastroenterology</i> , <b>2015</b> , 149, 1345-60	13.3	230
346	Statin use and non-alcoholic steatohepatitis in at risk individuals. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 705-12	13.4	227
345	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , <b>2018</b> , 155, 411-421.e4	13.3	201

344	Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. <i>Hepatology</i> , <b>2004</b> , 40, 883-91	11.2	199
343	Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. <i>Gastroenterology</i> , <b>2009</b> , 136, 1618-28.e2	13.3	197
342	Non-alcoholic fatty liver disease pathogenesis: the present and the future. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, 615-25	3.3	190
341	Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?. <i>Hepatology</i> , <b>2001</b> , 33, 333-8	11.2	182
340	Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 955-65		179
339	The long-term course of chronic hepatitis B. <i>Hepatology</i> , <b>1999</b> , 30, 257-64	11.2	170
338	Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. <i>Hepatology</i> , <b>2004</b> , 39, 333-42	11.2	169
337	Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. <i>Digestive Diseases and Sciences</i> , <b>1983</b> , 28, 39-43	4	159
336	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. <i>Gastroenterology</i> , <b>2016</b> , 150, 145-155.e4; quiz e15-6	13.3	156
335	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 325-336	18.8	153
334	Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1136-44	0.7	149
333	Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 2112-20	0.7	148
332	Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , <b>2006</b> , 43, 64-71	11.2	147
331	Characteristics of hepatocellular carcinoma in Italy. <i>Journal of Hepatology</i> , <b>1998</b> , 29, 944-52	13.4	134
330	Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. <i>Hepatology</i> , <b>1983</b> , 3, 545-9	11.2	134
329	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2015</b> , 62, 1101-10	11.2	131
328	Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 712-23	3.3	128
327	The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. <i>Liver International</i> , <b>2010</b> , 30, 342-55	7.9	128

326	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 928-33	13.4	115
325	Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). <i>Hepatology</i> , <b>1999</b> , 30, 238-43	11.2	107
324	Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. <i>Gastroenterology</i> , <b>2016</b> , 151, 130-139.e2	13.3	107
323	Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. <i>Hepatology</i> , <b>2012</b> , 55, 1317-23	11.2	105
322	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 688-695	6.1	104
321	Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 1350-60	6.1	104
320	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , <b>2020</b> , 71, 1213-1227		104
319	Hepatitis B virus reactivation and alemtuzumab therapy. <i>European Journal of Haematology</i> , <b>2005</b> , 74, 254-8	3.8	97
318	Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 757-66	6.1	95
317	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , <b>2015</b> , 35, 1566-73	7.9	94
316	A multicenter randomized controlled trial of recombinant interferon- $\alpha$ 2b in patients with acute transfusion-associated hepatitis C. <i>Hepatology</i> , <b>1994</b> , 19, 19-22	11.2	93
315	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , <b>2012</b> , 56, 850-60	11.2	91
314	Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. <i>Journal of Hepatology</i> , <b>2005</b> , 42, 535-40	13.4	89
313	Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 792-800	13.4	88
312	Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. <i>Journal of Hepatology</i> , <b>2007</b> , 47, 484-91	13.4	84
311	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1604-1611.e1	6.9	83
310	Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. <i>Hepatology</i> , <b>2015</b> , 62, 784-91	11.2	83
309	2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. <i>Liver International</i> , <b>2012</b> , 32 Suppl 1, 2-8	7.9	83

308	Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. <i>Journal of Hepatology</i> , <b>2004</b> , 41, 474-81	13.4	83
307	Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , <b>2014</b> , 9, e87523	3.7	83
306	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 265-273	13.4	80
305	IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. <i>Human Immunology</i> , <b>2003</b> , 64, 674-80	2.3	80
304	Impact of COVID-19 on global HCV elimination efforts. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 31-36	13.4	80
303	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. <i>Hepatology</i> , <b>2013</b> , 57, 1046-54	11.2	78
302	Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 271-9	13.4	77
301	Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. <i>Hepatology</i> , <b>2010</b> , 52, 1543-52	11.2	76
300	Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission. <i>Journal of Medical Virology</i> , <b>2002</b> , 67, 339-44	19.7	76
299	Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. <i>Journal of Hepatology</i> , <b>1993</b> , 18, 154-62	13.4	76
298	Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 238-47	6.1	74
297	The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). <i>Journal of Hepatology</i> , <b>1994</b> , 21, 646-55	13.4	73
296	IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1356-62	13.4	72
295	Decrease in HDV endemicity in Italy. <i>Journal of Hepatology</i> , <b>1997</b> , 26, 20-4	13.4	72
294	Long-term course of interferon-treated chronic hepatitis C. <i>Journal of Hepatology</i> , <b>1998</b> , 28, 531-7	13.4	71
293	Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. <i>Gut</i> , <b>2001</b> , 48, 843-8	19.2	69
292	Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 2628-31	5.6	69
291	When and how to treat acute hepatitis C?. <i>Journal of Hepatology</i> , <b>2003</b> , 39, 1056-62	13.4	68

290	Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 867-74	3.4	67
289	Hepatitis C virus (HCV) infection: a systemic disease. <i>Molecular Aspects of Medicine</i> , <b>2008</b> , 29, 85-95	16.7	67
288	Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. <i>Journal of Hepatology</i> , <b>1996</b> , 24, 517-24	13.4	66
287	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. <i>Blood</i> , <b>2010</b> , 116, 2875-83	2.2	65
286	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , <b>2014</b> , 59, 1692-705	11.2	64
285	Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 62-75	6.1	64
284	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 65-71	13.4	63
283	Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 861-862	13.4	63
282	Interferon as treatment for acute hepatitis C. A meta-analysis. <i>Digestive Diseases and Sciences</i> , <b>1996</b> , 41, 1248-55	4	63
281	Cardiovascular diseases and HCV infection: a simple association or more?. <i>Gut</i> , <b>2014</b> , 63, 369-75	19.2	60
280	Multimodal approaches to the treatment of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2009</b> , 6, 159-69	24.2	59
279	The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 25, 1181-91	6.1	59
278	Is autoimmune chronic active hepatitis a HCV-related disease?. <i>Journal of Hepatology</i> , <b>1991</b> , 13, 56-60	13.4	59
277	Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. <i>World Journal of Hepatology</i> , <b>2012</b> , 4, 256-61	3.4	59
276	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 160-168	6.1	58
275	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. <i>Liver International</i> , <b>2011</b> , 31, 507-15	7.9	58
274	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 523-9	13.4	57
273	Clinical significance of antibody to the hepatitis delta virus in symptomless HBsAg carriers. <i>Lancet, The</i> , <b>1985</b> , 2, 356-8	40	57

272	Management of infections pre- and post-liver transplantation: report of an AISF consensus conference. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1075-89	13.4	56
271	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. <i>Hepatology</i> , <b>2009</b> , 49, 195-203	11.2	56
270	Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. <i>Pharmacoeconomics</i> , <b>2004</b> , 22, 257-65	4.4	55
269	Hepatitis C virus replication in 'autoimmune' chronic hepatitis. <i>Journal of Hepatology</i> , <b>1991</b> , 13, 364-7	13.4	55
268	Hepatitis C and diabetes: the inevitable coincidence?. <i>Expert Review of Anti-Infective Therapy</i> , <b>2009</b> , 7, 293-308	5.5	54
267	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , <b>2017</b> , 37, 1157-1166	7.9	53
266	Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. <i>Current Pharmaceutical Design</i> , <b>2010</b> , 16, 741-52	3.3	52
265	Extrahepatic manifestations of hepatitis C virus infection. <i>Clinics in Liver Disease</i> , <b>2008</b> , 12, 611-36, ix	4.6	52
264	Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. <i>Hepatology</i> , <b>2008</b> , 48, 28-37	11.2	49
263	Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , <b>2004</b> , 99, 1490-6	0.7	49
262	Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 2472-7	0.7	48
261	The epidemiology of hepatitis delta infection in Italy. Promoting Group. <i>Journal of Hepatology</i> , <b>1992</b> , 15, 211-5	13.4	48
260	Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?. <i>Liver International</i> , <b>2014</b> , 34 Suppl 1, 85-90	7.9	47
259	PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e74089	3.7	47
258	Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 196-204	6.1	46
257	Prevention of hepatocellular carcinoma. <i>Clinics in Liver Disease</i> , <b>2005</b> , 9, 329-46, viii	4.6	46
256	Baseline sero-epidemiology of hepatitis B virus infection in children and teenagers in Italy. A survey before mass hepatitis B vaccination. <i>Journal of Infection</i> , <b>1991</b> , 22, 191-9	18.9	46
255	Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. <i>British Journal of Haematology</i> , <b>2010</b> , 148, 476-9	4.5	45

254	Herbal hepatotoxicity: a hidden epidemic. <i>Internal and Emergency Medicine</i> , <b>2013</b> , 8, 13-22	3.7	43
253	Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 3625-34		43
252	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2310-2319.e6	6.9	42
251	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , <b>2015</b> , 8, 1037-46	4.1	42
250	Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. <i>Gastroenterology</i> , <b>2013</b> , 145, 1035-1044.e5	13.3	42
249	Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 486-93	3.4	42
248	IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. <i>Haematologica</i> , <b>2012</b> , 97, 679-86	6.6	41
247	Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. <i>Haematologica</i> , <b>2008</b> , 93, 1243-6	6.6	41
246	Does an 'autoimmune' profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey. <i>Journal of Viral Hepatitis</i> , <b>2004</b> , 11, 257-62	3.4	41
245	Pegylated interferons for chronic hepatitis B. <i>Antiviral Research</i> , <b>2003</b> , 60, 87-9	10.8	40
244	Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. <i>Journal of Hepatology</i> , <b>2000</b> , 33, 456-62	13.4	40
243	Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2000</b> , 14, 1645-52	6.1	39
242	Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 649-654	1.6	39
241	Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186136	3.7	38
240	HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. <i>Journal of Hepatology</i> , <b>2004</b> , 40, 831-6	13.4	38
239	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. <i>Liver International</i> , <b>2019</b> , 39, 1742-1754	7.9	37
238	Familiar clustering and spreading of hepatitis delta virus infection. <i>Journal of Hepatology</i> , <b>1985</b> , 1, 221-6	13.4	37
237	Management of infections in cirrhotic patients: report of a consensus conference. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 204-12	3.3	36



236	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , <b>2020</b> , 296, 40-47	3.1	36
235	The UCP2 -866G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. <i>Liver International</i> , <b>2015</b> , 35, 1574-80	7.9	35
234	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 658-66	13.4	34
233	Implication of normal liver enzymes in liver disease. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 529-36	3.4	34
232	Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis. <i>Journal of Medical Virology</i> , <b>1992</b> , 38, 200-6	19.7	34
231	Clinical implications of the hyperdynamic syndrome in cirrhosis. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 795-802	3.9	33
230	Coeliac disease: oral ulcer prevalence, assessment of risk and association with gluten-free diet in children. <i>Digestive and Liver Disease</i> , <b>2008</b> , 40, 104-7	3.3	33
229	Oral pathology in untreated coeliac [corrected] disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 1529-36	6.1	33
228	HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy). <i>Journal of Hepatology</i> , <b>1996</b> , 25, 583-90	13.4	32
227	Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1995</b> , 40, 33-40	4	31
226	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2660-2669	5.6	30
225	White paper of Italian Gastroenterology: delivery of services for digestive diseases in Italy: weaknesses and strengths. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 579-89	3.3	30
224	Hepatitis C virus and Sjögren's syndrome. <i>Lancet, The</i> , <b>1992</b> , 339, 989-90	4.0	30
223	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. <i>Liver International</i> , <b>2017</b> , 37, 1526-1534	7.9	29
222	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , <b>2017</b> , 6, 1930-1940	4.8	29
221	Inguinal hernioplasty improves the quality of life in patients with cirrhosis. <i>American Journal of Surgery</i> , <b>2008</b> , 196, 373-8	2.7	29
220	Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?. <i>Journal of Hepatology</i> , <b>2007</b> , 47, 580-7	13.4	29
219	Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 1116-20	3.3	28

218	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 1169-76	13.4	28
217	Hepatocellular cancer: optimal strategies for screening and surveillance. <i>Digestive Diseases</i> , <b>2009</b> , 27, 142-7	3.2	28
216	Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 823-31	1.6	28
215	Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life. <i>Digestive and Liver Disease</i> , <b>2005</b> , 37, 850-60	3.3	28
214	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2408-2416	6.7	28
213	Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 311-7.e1	6.9	27
212	CT enterography as a powerful tool for the evaluation of inflammatory activity in Crohn's disease: relationship of CT findings with CDAI and acute-phase reactants. <i>Radiologia Medica</i> , <b>2014</b> , 119, 658-66	6.5	27
211	Hyperferritinemia is a risk factor for steatosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 2132-8	5.6	27
210	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , <b>2017</b> , 37, 1389-1396	7.9	26
209	Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 259-65	3.3	25
208	Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. <i>Journal of Clinical Gastroenterology</i> , <b>2012</b> , 46, 504-8	3	25
207	Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. <i>Digestive and Liver Disease</i> , <b>2008</b> , 40, 684-9	3.3	25
206	Characteristics of liver cirrhosis in Italy: results from a multicenter national study. <i>Digestive and Liver Disease</i> , <b>2004</b> , 36, 56-60	3.3	25
205	Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection. <i>Journal of Hepatology</i> , <b>1991</b> , 12, 64-9	13.4	25
204	Serum $\gamma$ -glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. <i>PLoS ONE</i> , <b>2012</b> , 7, e51165	3.7	24
203	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 404-10	3.3	24
202	Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 585-92	3.3	24
201	Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP). <i>Hepatology</i> , <b>1999</b> , 30, 801-7	11.2	24

200	Autoimmunity in chronic liver disease caused by hepatitis delta virus. <i>Journal of Clinical Pathology</i> , <b>1986</b> , 39, 897-9	3.9	24
199	Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2019</b> , 39, 1325-1334	7.9	23
198	Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?. <i>Liver International</i> , <b>2018</b> , 38, 2190-2198	7.9	23
197	Current and future HCV therapy: do we still need other anti-HCV drugs?. <i>Liver International</i> , <b>2015</b> , 35 Suppl 1, 4-10	7.9	23
196	Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 16-21	13.4	23
195	Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 143-8	3.3	23
194	Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 469-74	3.4	23
193	Treatment options in HBV. <i>Journal of Hepatology</i> , <b>2006</b> , 44, S77-83	13.4	23
192	Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey. <i>Clinical Medicine Insights Gastroenterology</i> , <b>2014</b> , 7, 25-31		22
191	Second generation tests in diagnosis of chronic hepatitis C. <i>Lancet, The</i> , <b>1991</b> , 337, 1354	4.0	22
190	Immunological alterations in hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 8916-23	5.6	22
189	Hepatic benefits of HCV cure. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1548-1556	13.4	22
188	The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 193-200	5.6	21
187	SARS-CoV-2 Viral Load, IFN Polymorphisms and the Course of COVID-19: An Observational Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	21
186	NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e68364	3.7	20
185	Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. <i>PLoS ONE</i> , <b>2013</b> , 8, e70016	3.7	20
184	Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 603-13	6.1	20
183	Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 675-81	13.4	20

182	Phylogenetic reconstruction of HCV genotype 1b dissemination in a small city centre: the Camporeale model. <i>Journal of Medical Virology</i> , <b>2008</b> , 80, 1723-31	19.7	20
181	HCV infection and oral lichen planus: a weak association when HCV is endemic. <i>Journal of Viral Hepatitis</i> , <b>2004</b> , 11, 465-70	3.4	20
180	The aetiology of chronic hepatitis in Italy: results from a multicentre national study. <i>Digestive and Liver Disease</i> , <b>2004</b> , 36, 829-33	3.3	20
179	Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months. <i>Journal of Hepatology</i> , <b>1996</b> , 24, 539-46	13.4	20
178	The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. <i>Current Pharmaceutical Design</i> , <b>2004</b> , 10, 2123-30	3.3	20
177	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. <i>Liver International</i> , <b>2020</b> , 40, 1545-1555	7.9	19
176	How to optimize HCV therapy in genotype 1 patients: predictors of response. <i>Liver International</i> , <b>2013</b> , 33 Suppl 1, 23-9	7.9	19
175	Halitosis: could it be more than mere bad breath?. <i>Internal and Emergency Medicine</i> , <b>2011</b> , 6, 315-9	3.7	19
174	Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?. <i>Liver International</i> , <b>2009</b> , 29, 1171-7	7.9	19
173	A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. <i>Journal of Medical Virology</i> , <b>1997</b> , 51, 17-24	19.7	19
172	Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1998</b> , 12, 1091-9	6.1	19
171	Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. <i>Digestive and Liver Disease</i> , <b>2005</b> , 37, 882-5	3.3	19
170	Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. <i>Gut</i> , <b>2002</b> , 51, 864-9	19.2	19
169	A retrospective study of the role of delta agent infection in children with HBsAg-positive chronic hepatitis. <i>Hepatology</i> , <b>1985</b> , 5, 7-9	11.2	19
168	Needle track seeding following percutaneous procedures for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , <b>2009</b> , 1, 62-6	3.4	19
167	Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. <i>Journal of Medical Economics</i> , <b>2015</b> , 18, 678-90	2.4	18
166	A simplified clinical risk score predicts the need for early endoscopy in non-variceal upper gastrointestinal bleeding. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 783-7	3.3	18
165	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , <b>2017</b> , 66, 1814-1825	11.2	18

164	Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. <i>World Journal of Hepatology</i> , <b>2013</b> , 5, 685-91	3.4	18
163	Clinical trial results of peginterferons in combination with ribavirin. <i>Seminars in Liver Disease</i> , <b>2003</b> , 23 Suppl 1, 35-46	7.3	18
162	Anti-HCV, anti-GOR, and autoimmunity. <i>Lancet, The</i> , <b>1992</b> , 339, 871-872	4.0	18
161	Refining sorafenib therapy: lessons from clinical practice. <i>Future Oncology</i> , <b>2015</b> , 11, 449-65	3.6	17
160	Fluoroquinolone-induced liver injury: three new cases and a review of the literature. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 525-32	2.8	17
159	Should cirrhosis change our attitude towards treating non-hepatic cancer?. <i>Liver International</i> , <b>2012</b> , 32, 21-7	7.9	17
158	Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 227-35	6.1	17
157	Treatment of hepatitis C: critical appraisal of the evidence. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 399-408	4	17
156	Risk management of HBsAg or anti-HCV positive healthcare workers in hospital. <i>Digestive and Liver Disease</i> , <b>2001</b> , 33, 795-802	3.3	17
155	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> , 31, 2345-2353	4.5	17
154	PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 939-48	6.1	16
153	Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 113-21	3.4	16
152	Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. <i>ClinicoEconomics and Outcomes Research</i> , <b>2014</b> , 6, 303-10	1.7	16
151	Oesophagogastroduodenoscopy in patients with cirrhosis: Extending the range of detection beyond portal hypertension. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 48-53	3.3	16
150	FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC program. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 227-35	13.4	16
149	HCV genotypes in Sicily: is there any evidence of a shift?. <i>Journal of Medical Virology</i> , <b>2009</b> , 81, 1040-6	19.7	16
148	Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract. <i>Pathology Research and Practice</i> , <b>2003</b> , 199, 65-70	3.4	16
147	Third-generation hepatitis C virus tests in asymptomatic anti-HCV-positive blood donors. <i>Journal of Hepatology</i> , <b>1994</b> , 21, 730-4	13.4	16

146	Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. <i>Liver International</i> , <b>2012</b> , 32, 1443-50	7.9	15
145	Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 674-80	3.3	15
144	Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 397-405	3.4	15
143	Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 523-30	3.4	15
142	Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 51, 364-70	4.5	15
141	Detection of hepatitis delta virus RNA in chronic liver disease. <i>Journal of Hepatology</i> , <b>1989</b> , 9, 23-8	13.4	15
140	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 731-741	3.3	14
139	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 936-42	3.3	14
138	Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19, 766-74	3.4	14
137	Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?. <i>Liver International</i> , <b>2018</b> , 38, 2108-2116	7.9	13
136	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 427-434	18.8	13
135	Parvovirus B19 and "cryptogenic" chronic hepatitis. <i>Journal of Hepatology</i> , <b>2003</b> , 38, 375-6	13.4	13
134	Long-term evolution of chronic delta hepatitis in children. <i>Journal of Pediatrics</i> , <b>1993</b> , 122, 736-8	3.6	13
133	Interleukin-2, interleukin-2 receptor and gamma-interferon synthesis by peripheral blood mononuclear cells in chronic hepatitis delta virus infection. <i>Journal of Hepatology</i> , <b>1989</b> , 8, 358-66	13.4	13
132	Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e110857	3.7	13
131	SARS-CoV-2 infection in patients with a normal or abnormal liver. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 4-11	3.4	13
130	Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 477-86	6.1	12
129	Clinical course and management of acute and chronic viral hepatitis during pregnancy. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 515-23	3.4	12

128	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 995-1005	3.3	12
127	Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 740-749	6.1	12
126	Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. <i>Journal of Viral Hepatitis</i> , <b>2002</b> , 9, 354-9	3.4	12
125	TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , <b>2016</b> , 36, 198-204	7.9	12
124	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 12-19	3.4	12
123	HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 1430-3	13.4	11
122	Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?. <i>Expert Review of Anticancer Therapy</i> , <b>2013</b> , 13, 1355-61	3.5	11
121	Osteodystrophy in chronic liver diseases. <i>Internal and Emergency Medicine</i> , <b>2013</b> , 8, 377-88	3.7	11
120	Oral mucosa of coeliac disease patients produces antiendomysial and antitransglutaminase antibodies: the diagnostic usefulness of an in vitro culture system. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 25, 1471-7	6.1	11
119	Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases. <i>Journal of Viral Hepatitis</i> , <b>2006</b> , 13, 351-4	3.4	11
118	Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. <i>Digestive Diseases and Sciences</i> , <b>1999</b> , 44, 1013-9	4	11
117	Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 118-125	3.4	11
116	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 174-82	3.4	10
115	Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 878-884.e1	6.9	10
114	Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 337-42	3.7	10
113	Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 790-800	3.4	10
112	Will the COVID-19 pandemic affect HCV disease burden?. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 947-949	3.3	10
111	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10

110	N5SA Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. <i>Cells</i> , <b>2019</b> , 8,	7.9	9
109	Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 245-50	3.3	9
108	Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis. <i>Gut</i> , <b>2011</b> , 60, 1023	19.2	9
107	Metastatic hepatocellular carcinoma of the parotid region without lung metastasis: a case report. <i>International Journal of Oral and Maxillofacial Surgery</i> , <b>2009</b> , 38, 696-8	2.9	9
106	Multiple voltage-gradient gel electrophoresis system. <i>Electrophoresis</i> , <b>2001</b> , 22, 29-32	3.6	9
105	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. <i>Liver International</i> , <b>2020</b> , 40, 2820-2827	7.9	9
104	Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. <i>Epidemics</i> , <b>2021</b> , 34, 100442	5.1	9
103	Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. <i>Clinical Transplantation</i> , <b>2018</b> , 32, e13165	3.8	9
102	Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 915-921	3.3	8
101	Extrahepatic Manifestations of Chronic Viral C Hepatitis. <i>Gastroenterology Clinics of North America</i> , <b>2020</b> , 49, 347-360	4.4	8
100	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 818-25	3.3	8
99	Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19, 465-72	3.4	8
98	Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 111-8	1.6	8
97	Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. <i>Liver International</i> , <b>2011</b> , 31 Suppl 1, 36-44	7.9	8
96	Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. <i>Journal of Medical Virology</i> , <b>2006</b> , 78, 1304-11	19.7	8
95	From viral pathobiology to the treatment of hepatitis B virus infection EASL Monothematic Conference (Istanbul, Turkey, October 6-8, 2005). <i>Journal of Hepatology</i> , <b>2006</b> , 44, 1186-95	13.4	8
94	Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review. <i>Liver International</i> , <b>2009</b> , 29 Suppl 1, 31-8	7.9	7
93	Chronic hepatitis B: who to treat and which choice of treatment?. <i>Expert Review of Anti-Infective Therapy</i> , <b>2009</b> , 7, 281-91	5.5	7



92	Early virologic response with pegylated interferons. <i>Digestive and Liver Disease</i> , <b>2004</b> , 36 Suppl 3, S340-33,3		7
91	Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis. <i>Digestive and Liver Disease</i> , <b>2002</b> , 34, 656-9	3.3	7
90	Host and viral features in chronic HCV infection: relevance to interferon responsiveness. <i>Research in Virology</i> , <b>1995</b> , 146, 273-8		7
89	Polyalbumin receptors, hepatitis B surface antigen (HBsAg), and HBsAg/IgM complexes in HBsAg positive patients with and without delta superinfection. <i>Journal of Medical Virology</i> , <b>1985</b> , 15, 383-8	19.7	7
88	Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements. <i>Liver International</i> , <b>2021</b> , 41, 649-655	7.9	7
87	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , <b>2018</b> , 46, 607-615	5.8	7
86	Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. <i>Scientific Reports</i> , <b>2019</b> , 9, 585	4.9	6
85	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 469-80	3.4	6
84	Phylogenetic analysis of isolates from new cases of HBV infection in Southern Italy. <i>Infection, Genetics and Evolution</i> , <b>2012</b> , 12, 1591-6	4.5	6
83	PEG IFN alfa-2a vs. alfa-2b: and the winner is ...?. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 133-5	13.4	6
82	Soluble complement receptor type 1 (sCR1) in chronic liver diseases: serum levels at different stages of liver diseases. <i>Clinical and Experimental Immunology</i> , <b>1998</b> , 114, 102-5	6.2	6
81	Treating patients with HCV genotype 1 and low viraemia: more than meets the eye. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 4-7	13.4	6
80	Treatment with interferon alfa-2b of chronic HDV hepatitis in children. <i>Journal of Hepatology</i> , <b>1990</b> , 11, S175	13.4	6
79	Severe rifampicin-associated liver failure in patients with compensated cirrhosis. <i>Lancet, The</i> , <b>1978</b> , 1, 774	4.0	6
78	The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. <i>Liver International</i> , <b>2021</b> , 41, 934-948	7.9	6
77	HCV: the best cure possible or the best possible cure?. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 627-9	3.4	5
76	High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2001</b> , 15, 953-8	6.1	5
75	Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease?. <i>Digestive and Liver Disease</i> , <b>2002</b> , 34, 53-8	3.3	5

74	A performance evaluation of the expert system 'Jaundice' in comparison with that of three hepatologists. <i>Journal of Hepatology</i> , <b>1991</b> , 13, 279-85	13.4	5
73	PRIMARY BILIARY CIRRHOSIS AND CHOLANGIOLITHIASIS DISEASE. <i>Lancet, The</i> , <b>1978</b> , 311, 713-714	4.0	5
72	Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?. <i>Annali Dell'istituto Superiore Di Sanita</i> , <b>2020</b> , 56, 325-329	1.6	5
71	Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. <i>Liver International</i> , <b>2020</b> , 40, 2590-2601	7.9	5
70	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , <b>2019</b> , 17, 117-138	4.3	5
69	Expert opinion on managing chronic HCV in patients with cardiovascular disease. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 35-46	1.6	5
68	Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1314-1317	3.3	4
67	Impact of HBV genotypes A and D genetic variability on infection evolution. <i>Infection, Genetics and Evolution</i> , <b>2015</b> , 33, 281-7	4.5	4
66	Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19, e120-5	3.4	4
65	Genetic predisposition to thrombophilia in inflammatory bowel disease. <i>Journal of Clinical Gastroenterology</i> , <b>2011</b> , 45, e25-9	3	4
64	Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42 Suppl 3, S287-92	3.3	4
63	Histomorphology of healthy oral mucosa in untreated celiac patients: unexpected association with spongiosis. <i>Journal of Oral Pathology and Medicine</i> , <b>2009</b> , 38, 34-41	3.3	4
62	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. <i>Liver Cancer</i> , <b>2022</b> , 11, 75-84	9.1	4
61	A multicenter randomized controlled trial of recombinant interferon- $\alpha$ 2b in patients with acute transfusion-associated hepatitis C <b>1994</b> , 19, 19		4
60	PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1979-1981	6.9	4
59	Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Viruses</i> , <b>2022</b> , 14, 986	6.2	4
58	Between reality and the guidelines: A survey on perception, diagnosis and management of hepatic encephalopathy in 201 Italian specialist centres. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 828-830	3.3	3
57	Reply to: "IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients". <i>Journal of Hepatology</i> , <b>2013</b> , 58, 403-4	13.4	3

56	Epicardial fat in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1215	13.4	3
55	HCV genotype 5: an orphan virus. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 263-9	1.6	3
54	Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 66-70	3.4	3
53	Surgery in patients with liver disease. <i>Hepatology</i> , <b>1999</b> , 30, 820-1	11.2	3
52	Hepatitis B vaccination of relatives of hepatitis B virus DNA positive carriers: an experience with plasma-derived vaccine. <i>European Journal of Epidemiology</i> , <b>1989</b> , 5, 65-9	12.1	3
51	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. <i>Cancers</i> , <b>2020</b> , 13,	6.6	3
50	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2020</b> , 30, 2103-2110	4.5	3
49	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1190-1199	3.4	3
48	Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 2389-2396	4	3
47	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 612-619	3.3	3
46	Current and future challenges in HCV: insights from an Italian experts panel. <i>Infection</i> , <b>2018</b> , 46, 147-163	5.8	3
45	Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. <i>Future Microbiology</i> , <b>2015</b> , 10, 977-88	2.9	2
44	HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors. <i>Infection, Genetics and Evolution</i> , <b>2014</b> , 23, 80-5	4.5	2
43	Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 26, 388-95	2.2	2
42	Adefovir for lamivudine resistant HBV: more than meets the eye. <i>Journal of Hepatology</i> , <b>2007</b> , 47, 618-9; author reply 619-20	13.4	2
41	Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms. <i>Digestive and Liver Disease</i> , <b>2005</b> , 37, 446-50	3.3	2
40	The natural history of chronic HDV infection. <i>Progress in Clinical and Biological Research</i> , <b>1993</b> , 382, 301-10		2
39	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1301-1307	3.3	2

38	Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1248-1255	0.7	2
37	Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. <i>Liver International</i> , <b>2021</b> ,	7.9	2
36	Reply to: "Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients". <i>Journal of Hepatology</i> , <b>2014</b> , 60, 677-8	13.4	1
35	Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?. <i>Hepatology</i> , <b>2012</b> , 55, 1309; author reply 1309-10	11.2	1
34	Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment. <i>Journal of Clinical Gastroenterology</i> , <b>2013</b> , 47, 786-93	3	1
33	Occult hepatitis B virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C. <i>Hepatology</i> , <b>2011</b> , 54, 373-4; author reply 374	11.2	1
32	A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions.. <i>BMC Infectious Diseases</i> , <b>2022</b> , 22, 58	4	1
31	Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial.. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2022</b> ,	4.5	1
30	IgM anti-HBc in acute and chronic hepatitis B virus (HBV) infection: diagnostic value and correlation with viral replication and disease activity. <i>Bollettino Dell'istituto Sieroterapico Milanese</i> , <b>1988</b> , 67, 275-82		1
29	Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy.. <i>BMC Infectious Diseases</i> , <b>2022</b> , 22, 3	4	1
28	Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8-Weeks' Glecaprevir/Pibrentasvir Therapy. <i>Infectious Diseases and Therapy</i> , <b>2021</b> , 10, 763-774	6.2	1
27	Visceral adiposity index and exercise in non-alcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 490-490	6.1	0
26	A patient with acute hepatitis C and possible IFN toxicity. <i>Digestive and Liver Disease</i> , <b>2003</b> , 35, 372-3	3.3	0
25	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , <b>2020</b> , 15, e0243590	3.7	0
24	Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways. <i>Advances in Therapy</i> , <b>2021</b> , 38, 1397-1403	4.1	0
23	Response to Dr. Sertoglu and colleagues. <i>Liver International</i> , <b>2015</b> , 35, 285-6	7.9	
22	EASL Recognition Awardee 2020: Prof. Giovanna Fattovich. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 484-486	13.4	
21	Can we prevent and modify cardiometabolic disorders by controlling HCV infection?. <i>Gut</i> , <b>2018</b> , 67, 403-404		

20	Considerations regarding the alleged association between Herbalife products and cases of hepatotoxicity: a rebuttal. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 601-2	3-7
19	Reply to: "is industrial fructose just a marker of an unhealthy dietary pattern?". <i>Journal of Hepatology</i> , <b>2014</b> , 61, 173-5	13-4
18	Reply: To PMID 22135089. <i>Hepatology</i> , <b>2013</b> , 57, 422	11.2
17	Hepatitis Due to Non-AE Viruses <b>2011</b> , 427-437	
16	Is liver stiffness measurement unreliable in obese patients? authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 255-256	6.1
15	Hyperuricemia in non-alcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 1043-1044	6.1
14	Reply:. <i>Hepatology</i> , <b>2009</b> , 49, 1394-1395	11.2
13	Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy. <i>Hepatology</i> , <b>2010</b> , 51, 1858-1858.2	
12	Reply:. <i>Hepatology</i> , <b>2010</b> , 51, 2230-2230	11.2
11	Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 1045-9	1.6
10	Introduction. Necroinflammation and the course of chronic hepatitis. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39 Suppl 3, S369-71	3-3
9	Response to letter from Professor Peter Ferenci. <i>Digestive and Liver Disease</i> , <b>2005</b> , 37, 808-809	3-3
8	Epidemiology of viral hepatitis and HCC in Italy. <i>International Hepatology Communications</i> , <b>1996</b> , 5, 10-13	
7	Hepatitis C virus replication in chronic liver disease. <i>Journal of Hepatology</i> , <b>1991</b> , 13 Suppl 4, S40-1	13.4
6	Is hepatocellular carcinoma risk impacted favorably or unfavorably by hepatitis C virus therapy with direct-acting antivirals? <b>2020</b> , 231-237	
5	Hepatitis B: Prognosis and Treatment <b>2010</b> , 448-464	
4	Genotype 1 Relapsers and Non-Responders84-89	
3	Reply to: "Hepatic benefits of HCV cure: Don't forget coagulation!". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 969	13.4

2 Reply. *Hepatology*, **2016**, 64, 701

11.2

1 Hepatitis B- a Therapeutic Vaccine: Hope or Hype?230-235